| Literature DB >> 24475279 |
Jason Y Y Wong1, Immaculata De Vivo2, Xihong Lin3, Shona C Fang4, David C Christiani5.
Abstract
BACKGROUND: Chronic inflammation from recurring trauma is an underlying pathophysiological basis of numerous diseases. Furthermore, it may result in cell death, scarring, fibrosis, and loss of tissue function. In states of inflammation, subsequent increases in oxidative stress and cellular division may lead to the accelerated erosion of telomeres, crucial genomic structures which protect chromosomes from decay. However, the association between plasma inflammatory marker concentrations and telomere length has been inconsistent in previous studies.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24475279 PMCID: PMC3903646 DOI: 10.1371/journal.pone.0087348
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Repeated-Measures Data Collection of the Harvard Boilermakers Longitudinal Study.
Characteristics of the Harvard Boilermakers Longitudinal Study Population at Baseline.
| Variable | Total n = 87 | Mean Relative | |||
| Frequency | (%) | Telomere Length | Std. Dev. | p-value | |
| Current Smoking Status | |||||
| Non-smoker | 52 | 59.8 | 0.60 | 0.18 | 0.22 |
| Smoker | 31 | 35.6 | 0.66 | 0.17 | |
| Past Smoking Status | |||||
| Never | 17 | 19.5 | 0.63 | 0.22 | 0.99 |
| Ever | 47 | 54.0 | 0.63 | 0.17 | |
| Self-Reported Race | |||||
| White | 71 | 81.6 | 0.62 | 0.17 | 0.71 |
| African-American | 7 | 8.0 | 0.61 | 0.22 | |
| Hispanic | 3 | 3.4 | 0.66 | 0.28 | |
| Asian | 2 | 2.3 | 0.76 | 0.11 | |
|
|
|
|
| ||
| Age | 41.5 | 13.0 | 40.0 | 31.4–51.5 | |
| Number of Years Working as a Boilermaker | 11.1 | 10.5 | 9.0 | 3.0–11.5 | |
| Body Mass Index (BMI) (kg/m2) | 28.4 | 4.8 | 27.3 | 25.2–32.4 | |
| Relative Telomere Length (2−ddCt) | 0.63 | 0.18 | 0.60 | 0.5–0.7 | |
| Plasma C-Reactive Protein (CRP) Conc. (ng/mL) | 4790 | 7602 | 2740 | 896–6064 | |
| Plasma Serum Amyloid A (SAA) Conc. (ng/mL) | 5636 | 2881 | 8887 | 1260–6722 | |
| Plasma sICAM-1 Conc. (ng/mL) | 358 | 121 | 346 | 282–426 | |
| Plasma sVCAM-1 Conc. (ng/mL) | 531 | 181 | 527 | 406–628 | |
| Plasma VEGF Conc. (pg/mL) | 380 | 237 | 343 | 148–469 | |
| Plasma TNF-α (pg/mL) | 12.2 | 12.4 | 11.0 | 8.2–13.2 | |
| Plasma Interleukin-1 (IL-1β) Conc. (pg/mL) | 1.3 | 2.5 | 0.5 | 0–1.4 | |
| Plasma Interleukin-2 (IL-2) Conc. (pg/mL) | 4.4 | 14.4 | 2.0 | 1.0–3.4 | |
| Plasma Interleukin-6 (IL-6) Conc. (pg/mL) | 25.2 | 20.9 | 18.3 | 12.2–28.6 | |
| Plasma Interleukin-8 (IL-8) Conc. (pg/mL) | 17.7 | 17.0 | 14.6 | 10.0–19.8 | |
| Plasma Interleukin-10 (IL-10) Conc. (pg/mL) | 7.0 | 7.0 | 5.5 | 4.0–7.6 |
A two-sample Student's T-Test was used to compare telomere length in covariates with two categories (t-statistic), whereas a one-way ANOVA was used to evaluate covariates with three or more categories (F-statistic). *p-values≤0.05 were considered statistically significant.
Discrepancies in counts due to missing data.
The Association between Vascular Injury Inflammatory Markers and Telomere Length.
| C-Reactive Protein (CRP) | Estimate | 95%CI Lower | 95%CI Upper | p-value | |
| Main Effect (log ng/mL) | −2.6 x10−2 | −4.3 x10−2 | −8.2 x10−3 | 0.004 | * |
| Follow-up time (days) | −6.9 x10−4 | −1.4 x10−3 | 2.6 x10−5 | 0.059 | |
| Main Effect x Follow-up time | 4.8 x10−5 | −4.0 x10−5 | 1.4 x10−4 | 0.301 | |
|
| |||||
| Main Effect (log ng/mL) | −2.6 x10−2 | −4.5 x10−2 | −6.1 x10−3 | 0.011 | * |
| Follow-up time (days) | −8.8 x10−4 | −1.7 x10−3 | −6.0 x10−5 | 0.036 | |
| Main Effect x Follow-up time | 6.9 x10−5 | −3.0 x10−5 | 1.7 x10−4 | 0.176 | |
|
| |||||
| Main Effect (log ng/mL) | −2.4 x10−2 | −4.8 x10−2 | −9.0 x10−5 | 0.049 | |
| Follow-up time (days) | −1.5 x10−3 | −2.5 x10−3 | −5.6 x10−4 | 0.002 | * |
| Main Effect x Follow-up time | 2.1 x10−4 | 4.1 x10−5 | 3.8 x10−4 | 0.015 | |
|
| |||||
| Main Effect (log ng/mL) | −2.4 x10−2 | −4.6 x10−2 | −2.1 x10−3 | 0.032 | |
| Follow-up time (days) | −1.5 x10−3 | −2.4 x10−3 | −5.2 x10−4 | 0.003 | * |
| Main Effect x Follow-up time | 1.8 x10−4 | 3.1 x10−5 | 3.3 x10−4 | 0.019 |
Separate linear mixed models were used for each inflammatory marker. Models controlled for white blood cell count, neutrophil %, lymphocyte %, monocyte %, eosinophil %, current smoking intensity (cigarettes per day), age at baseline blood draw (years), BMI (log kg/m2), and years as a boilermaker (log years). Main effects were log-transformed to achieve a normal distribution.*p-values below the Bonferroni-adjusted α-level of 0.013 were considered statistically significant.
The estimate for the main effect represents the difference in telomere length per incremental ng/mL increase in the inflammatory marker at any follow-up time, controlling for other predictors. The estimate for follow-up time represents the rate of telomeric change; the difference in telomere length per day of follow-up when all other predictors are at zero. The estimate for the main effect x follow-up time interaction represents effect modification of the rate of telomeric change by the inflammatory marker; the change in telomere length per ng/mL increase in the inflammatory marker over each day of follow-up time, holding other predictors constant. 95% Confidence Intervals (95%CI) are the bounds in which with more independent samplings, the true estimate will fall within this range in 95% of those samplings.
The Association between Inflammatory Cytokines-Chemokines and Telomere Length.
| Interleukin-1β (IL-1β) | Estimate | 95%CI Lower | 95%CI Upper | p-value | |
| Main Effect (log pg/mL) | 1.7 x10−2 | −2.4 x10−2 | 5.8 x10−2 | 0.409 | |
| Follow-up time (days) | −3.3 x10−4 | −4.8 x10−4 | −1.8 x10−4 | <0.0001 | * |
| Main Effect x Follow-up time | 1.1 x10−5 | −1.7 x10−4 | 1.9 x10−4 | 0.903 | |
| Interleukin-2 (IL-2) | |||||
| Main Effect (log pg/mL) | −1.3 x10−3 | −3.9 x10−2 | 3.7 x10−2 | 0.948 | |
| Follow-up time (days) | −3.1 x10−4 | −5.1 x10−4 | −1.0 x10−4 | 0.003 | * |
| Main Effect x Follow-up time | −4.0 x10−5 | −2.3 x10−4 | 1.5 x10−4 | 0.661 | |
| Interleukin-6 (IL-6) | |||||
| Main Effect (log pg/mL) | 3.8 x10−2 | −8.8 x10−3 | 8.4 x10−2 | 0.110 | |
| Follow-up time (days) | 1.5 x10−5 | −5.9 x10−4 | 6.2 x10−4 | 0.959 | |
| Main Effect x Follow-up time | −1.2 x10−4 | −3.1 x10−4 | 7.2 x10−5 | 0.219 | |
| Interleukin-8 (IL-8) | |||||
| Main Effect (log pg/mL) | 2.0 x10−2 | −2.6 x10−2 | 6.5 x10−2 | 0.397 | |
| Follow-up time (days) | 1.0 x10−5 | −4.8 x10−4 | 5.0 x10−4 | 0.968 | |
| Main Effect x Follow-up time | −1.3 x10−4 | −3.1 x10−4 | 4.6 x10−5 | 0.146 | |
| Interleukin-10 (IL-10) | |||||
| Main Effect (log pg/mL) | −2.5 x10−2 | −6.9 x10−2 | 2.0 x10−2 | 0.269 | |
| Follow-up time (days) | −6.0 x10−4 | −9.7 x10−4 | −2.2 x10−4 | 0.002 | * |
| Main Effect x Follow-up time | 1.3 x10−4 | −4.0 x10−5 | 2.9 x10−4 | 0.133 | |
| Vascular Endo. Growth Factor (VEGF) | |||||
| Main Effect (log pg/mL) | 1.4 x10−2 | −1.8 x10−2 | 4.7 x10−2 | 0.383 | |
| Follow-up time (days) | −2.5 x10−4 | −1.1 x10−3 | 6.4 x10−4 | 0.581 | |
| Main Effect x Follow-up time | −2.0 x10−5 | −1.7 x10−4 | 1.4 x10−4 | 0.836 | |
| Tumor Necrosis Factor (TNF-α) | |||||
| Main Effect (log pg/mL) | 2.7 x10−3 | −4.5 x10−2 | 5.1 x10−2 | 0.911 | |
| Follow-up time (days) | −3.1 x10−4 | −8.6 x10−4 | 2.4 x10−4 | 0.261 | |
| Main Effect x Follow-up time | −1.0 x10−5 | −2.3 x10−4 | 2.1 x10−4 | 0.927 |
Separate linear mixed models were used for each cytokine/chemokine. Models controlled for white blood cell count, neutrophil %, lymphocyte %, monocyte %, eosinophil %, current smoking intensity (cigarettes per day), age at baseline blood draw (years), BMI (log kg/m2), and years as a boilermaker (log years). Main effects were log-transformed to achieve a normal distribution. *p-values below the Bonferroni-corrected α-level of 0.007 were considered statistically significant.
The estimate for the main effect represents the difference in telomere length per incremental pg/mL increase in the cytokine/chemokine at any follow-up time, controlling for other predictors. The estimate for follow-up time represents the rate of telomeric change; the difference in telomere length per day of follow-up when all other predictors are at zero. The estimate for the main effect x follow-up time interaction represents effect modification of the rate of telomeric change by the cytokine/chemokine; the change in telomere length per pg/mL increase in the cytokine/chemokine over each day of follow-up time, holding other predictors constant. 95% Confidence Intervals (95%CI) are the bounds in which with more independent samplings, the true estimate will fall within this range in 95% of those samplings.